Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia

About this update from Appili Therapeutics Inc Class A

[{"type":"text","content":"Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to TularemiaA review of recent findings suggests that Appili’s biodefense vaccine, ATI-1701, may have a role in preventing tularemia outbreaks\n\n\n\n HALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a publication in the journal\n \n Frontiers in Bacteriology\n \n on the prevention of tularemia, a potentially lethal bacterial infection. Dr. Carl Gelhaus, Ph.D., Director of NonClinical Research at Appili, together with researchers from the United States Air Force Academy (“USAFA”), and other U.S. based researchers published the manuscript, “\n \n The Immune Response to Francisella tularensis”.\n \n\n\n “Appili is developing ATI-1701, a biodefense vaccine, to protect warfighters from tularemia,” said Dr. Carl Gelhaus, Director of Non Clinical Research at Appili Therapeutics. “Together with the help of our colleagues, we can better understand host immune responses to tularemia, essential for advancing ATI-1701 towards the clinic. The insights shared in this article will directly inform our ongoing development and help refine immune response targets for ATI-1701.”\n \n\n The review consolidates recent findings on the immune system response to\n \n F. tularensis\n \n infections and suggests various means by which infections can be controlled. By examining diverse\n \n F. tularensis\n \n strains and animal models, the authors identify key correlates of protection and outline promising pathways for effective tularemia vaccine development.\n \n\n ATI-1701 is the Company’s potential first-in-class vaccine candidate for the prevention of infection with\n \n F. tularensis\n \n . Since it is a highly infectious pathogen capable of causing severe illness, medical countermeasures for\n \n F. tularensis\n \n are a top biodefense priority for governments around the world. There is currently no approved vaccine for the prevention of tularemia in the United States or other major global markets, strengthening ATI-1701’s position as a...

More updates from Appili Therapeutics Inc Class A